Literature DB >> 12109628

Glucagon administration elicits blunted GH but exaggerated ACTH response in obesity.

F Tassone1, S Grottoli, R Rossetto, B Maccagno, C Gauna, R Giordano, E Ghigo, M Maccario.   

Abstract

Reduction in both spontaneous and stimulated GH secretion in obesity has been clearly demonstrated. Mild hyperactivity of hypothalamus-pituitary-adrenal (HPA) axis has been also reported. Glucagon, at least after im administration, induces clear increase in either GH or ACTH and F levels but its effect on somatotroph and corticotroph secretion in obesity has never been studied. In 7 patients with abdominal obesity (OB, aged 24-42 yr, BMI: 29.1-43.9 kg/m2, waist/hip ratio [WHR]: 0.86-1.00) we studied the GH, ACTH and F responses to the im administration of glucagon (0.017 mg/kg at 0 min). The results in OB were compared with those in a group of 6 age-matched controls normal subjects (Ns aged 26-32 yr, BMI 19.7-22.5 kg/m2). In Ns glucagon administration induced clear increase in GH (peak vs baseline, mean+/-SE: 11.6+/-3.4 vs 3.3+/-0.7 microg/l, p<0.02), and ACTH (52.9+/-15.2 vs 19.0+/-1.5 pg/ml, p<0.02) levels which peaked at +150 and +165 min, respectively. Increase in F levels (222.3+/-23.8 vs 158.3+/-7.0 ng/ml, p<0.05) was also recorded but peaked at +180 min. In OB glucagon administration induced GH response (7.4+/-2.3 vs 0.8+/-0.6 microg/l) lower (p<0.05) than that recorded in Ns; when the GH responses were evaluated by co-variance analysis, a significant difference between the 2 groups was recorded in term of peaks but not of AUCs. On the other hand, the ACTH response to glucagon in OB was higher than that in Ns (11452.6+/-2447.7 vs 4892.2+/-719.4 pg/ml x min, p<0.05). The F response to glucagon in OB and Ns was, however, similar (24057.9+/-4109.1 vs 29835.9+/-1566.0 ng/ml x min). In conclusion, this study demonstrates that in obese patients the im administration of glucagon elicits blunted GH response but exaggerated ACTH increase which is uncoupled with the adrenal response. These findings agree with the existence of concomitant GH insufficiency and altered corticotroph function in obesity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12109628     DOI: 10.1007/BF03345499

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  53 in total

Review 1.  Dose-response aspects in the clinical assessment of the hypothalamo-pituitary-adrenal axis, and the low-dose adrenocorticotropin test.

Authors:  W Oelkers
Journal:  Eur J Endocrinol       Date:  1996-07       Impact factor: 6.664

2.  Interaction between glucagon and human corticotropin-releasing hormone or vasopressin on ACTH and cortisol secretion in humans.

Authors:  E Arvat; B Maccagno; J Ramunni; M Maccario; R Giordano; F Broglio; F Camanni; E Ghigo
Journal:  Eur J Endocrinol       Date:  2000-07       Impact factor: 6.664

3.  Growth-hormone release by glucagon.

Authors:  M L Mitchell; M J Byrne; J Silver
Journal:  Lancet       Date:  1969-02-08       Impact factor: 79.321

4.  Comparison of the diagnostic utility of the simplified and standard i.m. glucagon stimulation test (IMGST).

Authors:  S M Orme; A Price; A P Weetman; R J Ross
Journal:  Clin Endocrinol (Oxf)       Date:  1998-12       Impact factor: 3.478

5.  Interaction between glucagon and hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans.

Authors:  E Arvat; B Maccagno; J Ramunni; R Giordano; F Broglio; L Gianotti; M Maccario; F Camanni; E Ghigo
Journal:  Eur J Endocrinol       Date:  2000-11       Impact factor: 6.664

6.  The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution.

Authors:  R Pasquali; S Cantobelli; F Casimirri; M Capelli; L Bortoluzzi; R Flamia; A M Labate; L Barbara
Journal:  J Clin Endocrinol Metab       Date:  1993-08       Impact factor: 5.958

7.  Hyperactivity of the hypothalamo-pituitary-adrenal axis in obesity: a study of ACTH, AVP, beta-lipotrophin and cortisol responses to insulin-induced hypoglycaemia.

Authors:  J U Weaver; P G Kopelman; L McLoughlin; M L Forsling; A Grossman
Journal:  Clin Endocrinol (Oxf)       Date:  1993-09       Impact factor: 3.478

8.  Metabolic modulation of the growth hormone-releasing activity of hexarelin in man.

Authors:  M Maccario; E Arvat; M Procopio; L Gianotti; S Grottoli; B P Imbimbo; V Lenaerts; R Deghenghi; F Camanni; E Ghigo
Journal:  Metabolism       Date:  1995-01       Impact factor: 8.694

9.  Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity.

Authors:  M Maccario; M Procopio; S Grottoli; S E Oleandri; G M Boffano; M Taliano; F Camanni; E Ghigo
Journal:  Metabolism       Date:  1996-03       Impact factor: 8.694

10.  Glucagon stimulates GH secretion after intramuscular but not intravenous administration. Evidence against the assumption that glucagon per se has a GH-releasing activity.

Authors:  E Ghigo; E Bartolotta; E Imperiale; J Bellone; G Cardinale; G Aimaretti; M R Valetto; V Cherubini; M Maccario; D Cocchi
Journal:  J Endocrinol Invest       Date:  1994-12       Impact factor: 4.256

View more
  1 in total

1.  Systemic and local ACTH produced during inflammatory states promotes osteochondrogenic mesenchymal cell differentiation contributing to the pathologic progression of calcified atherosclerosis.

Authors:  Jodi F Evans; Louis Ragolia
Journal:  Med Hypotheses       Date:  2012-09-29       Impact factor: 1.538

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.